Search

everythinglearnresearchcommunity

for

Search:↓

Researchers found four genes that could help diagnose severe alopecia areata early.

A new model uses specific blood markers to predict if children's hair loss will return.

Alopecia Areata often runs in families and is linked to other autoimmune conditions.

Recognizing macro-TSH is crucial to avoid unnecessary treatments.

Atopic dermatitis increases the risk of some autoimmune diseases.

UVFD helps detect hair follicles in alopecia areata better than traditional methods.

Early recognition and a multidisciplinary approach are crucial for effectively managing complex autoimmune conditions like SLE with CAPS and AHA.

Dermal IgA deposition without symptoms is rare in Dermatitis herpetiformis risk groups.

Doctors should use a detailed patient history and physical exam to diagnose joint pain, and consult a rheumatologist early for suspected autoimmune diseases.

Ischemic modified albumin could be a new indicator of oxidative stress in people with alopecia areata.

Scientists made antibodies to tell cashmere and wool apart, which could improve how we identify animal fibers.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Hydroxychloroquine may cause false results in tuberculosis tests for patients with autoimmune skin diseases.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

Alopecia areata can be triggered by specific immune cells without genetic or environmental factors.

BKN-1 antibody targets specific keratin in basal cell epithelioma and normal skin basal cells.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

Detecting early breast arterial calcifications can help assess cardiovascular disease risk.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

Alopecia areata involves specific immune cells, offering potential treatment targets.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

Certain blood miRNAs are linked to severe alopecia areata and could lead to new treatments.

Alopecia areata involves both innate and adaptive immunity, with specific genes linked to the disease.

Generative AI tools like GPT-4o can effectively automate SALT scoring for alopecia areata, matching clinician accuracy.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Targeting the AhR pathway may help treat alopecia areata.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Patients with alopecia areata using Janus kinase inhibitors are not following lab monitoring guidelines.